Alessandro Riva, MD, to Join Gilead as Senior Vice President, Hematology and Oncology Therapeutic Area Head
January 03 2017 - 04:30PM
Business Wire
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that
Alessandro Riva, MD, will join the company as Senior Vice
President, Hematology and Oncology Therapeutic Area Head. In this
position, Dr. Riva will report to John McHutchison, MD, Executive
Vice President, Clinical Research and will have responsibility for
Gilead’s hematology and oncology programs. Alessandro will also
join Gilead’s Executive Committee.
Dr. Riva joins Gilead from Novartis Oncology, where he served as
Head, Global Oncology Development. He was responsible for the
development of more than 20 cancer compounds, including targeted
and immune-oncology therapies and for many worldwide regulatory
approvals of innovative medicines in both solid and hematological
malignancies. He was also a member of the Novartis Oncology
Division Executive Committee, Development Committee, Translational
and Early Development Committee and Innovation Management Board.
During his 12 year tenure at Novartis he was involved in several
worldwide drug approvals.
Prior to joining Novartis, Dr. Riva co-founded the Breast Cancer
International Research Group (BIRG) and Cancer International
Research Group (CIRG), for which he served as Chief Executive
Officer and Chief Medical Officer. He received his bachelor’s
degree in Medicine and also a Certificate Board in
Oncology/Hematology from the School of Medicine of Milan. He began
his career at the University Hospital of Milan where he treated
patients with hematological malignancies. He later moved to
clinical development leadership positions at Farmitalia Carlo Erba,
Rhone-Poulenc and Aventis where he successfully developed oncology
drugs at the global level. During his career, Alessandro has
authored or co-authored more than 100 oncology research manuscripts
and abstracts. He is a member of the American Society of Clinical
Oncology and the European Society for Medical Oncology.
“I am thrilled to welcome Alessandro, who brings a wealth of
experience and expertise in hematology/oncology drug development
and translational medicine,” said Dr. McHutchison. “His leadership
and proven track record developing therapies across the spectrum of
hematological malignancies and solid tumors will be instrumental as
we continue to grow and advance our pipeline of novel therapeutics
for people living with cancer.”
“I have always admired Gilead for its scientific focus and
data-driven approach to drug development,” said Dr. Riva. “I look
forward to working alongside Gilead’s dedicated and passionate
colleagues throughout the R&D organization to tackle the cancer
research and development challenge with a goal of improving the
lives of patients.”
About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers,
develops and commercializes innovative therapeutics in areas of
unmet medical need. The company’s mission is to advance the care of
patients suffering from life-threatening diseases. Gilead has
operations in more than 30 countries worldwide, with headquarters
in Foster City, California.
For more information on Gilead Sciences,
please visit the company’s website at www.gilead.com, follow
Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs
at 1-800-GILEAD-5 or 1-650-574-3000.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170103006171/en/
Gilead Sciences, Inc.Sung Lee, 650-524-7792InvestorsorNathan
Kaiser, 650-522-1853Media
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Feb 2024 to Mar 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Mar 2023 to Mar 2024